Author:
Lawitz Eric,Sulkowski Mark S,Ghalib Reem,Rodriguez-Torres Maribel,Younossi Zobair M,Corregidor Ana,DeJesus Edwin,Pearlman Brian,Rabinovitz Mordechai,Gitlin Norman,Lim Joseph K,Pockros Paul J,Scott John D,Fevery Bart,Lambrecht Tom,Ouwerkerk-Mahadevan Sivi,Callewaert Katleen,Symonds William T,Picchio Gaston,Lindsay Karen L,Beumont Maria,Jacobson Ira M
Reference17 articles.
1. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection;McHutchison;N Engl J Med,2009
2. Simeprevir with peginterferon alfa 2a or 2b plus ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled, phase 3 trial;Manns;Lancet,2014
3. Simeprevir with pegylated interferonalfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial;Jacobson;Lancet,2014
4. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial;Forns;Gastroenterology,2014
5. Reddy KR, Zeuzem S, Zoulim F, et al. A Phase III randomised, double-blind study to evaluate the efficacy, safety and tolerability of simeprevir vs telaprevir in combination with pegylated interferon and ribavirin in chronic hepatitis C virus genotype 1 treatment-experienced patients: the ATTAIN study. Asian Pacific Association for Study of the Liver (APASL); Brisbane, Australia; March 12–15, 2014.
Cited by
712 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献